585 related articles for article (PubMed ID: 11441410)
1. Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Rigas JR
Semin Oncol; 2001 Jun; 28(3 Suppl 9):15-20. PubMed ID: 11441410
[TBL] [Abstract][Full Text] [Related]
2. Challenging the platinum combinations in the chemotherapy of NSCLC.
Douillard JY; Eckardt J; Scagliotti GV
Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
[TBL] [Abstract][Full Text] [Related]
3. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
[TBL] [Abstract][Full Text] [Related]
4. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
[TBL] [Abstract][Full Text] [Related]
5. [Developed new agents for lung cancer].
Kato Y; Saijo N
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):218-23. PubMed ID: 11904983
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Ornstein DL; Nervi AM; Rigas JR
Ann Oncol; 1999; 10 Suppl 5():S35-40. PubMed ID: 10582137
[TBL] [Abstract][Full Text] [Related]
7. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Ohe Y; Ohashi Y; Kubota K; Tamura T; Nakagawa K; Negoro S; Nishiwaki Y; Saijo N; Ariyoshi Y; Fukuoka M
Ann Oncol; 2007 Feb; 18(2):317-23. PubMed ID: 17079694
[TBL] [Abstract][Full Text] [Related]
9. [Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Hosomi Y; Shibuya M
Gan To Kagaku Ryoho; 2007 Apr; 34(4):527-32. PubMed ID: 17431336
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy for advanced non-small cell lung cancer].
Ueoka H
Gan To Kagaku Ryoho; 2005 Jun; 32(6):770-6. PubMed ID: 15984514
[TBL] [Abstract][Full Text] [Related]
11. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
[TBL] [Abstract][Full Text] [Related]
12. [New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Mavroudis D
Rev Pneumol Clin; 2001 Nov; 57(5 Pt 2):S42-5. PubMed ID: 11924243
[No Abstract] [Full Text] [Related]
13. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
14. Rationale for non-platinum chemotherapy in advanced NSCLC.
Murren JR
Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
[TBL] [Abstract][Full Text] [Related]
15. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
16. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Baggstrom MQ; Stinchcombe TE; Fried DB; Poole C; Hensing TA; Socinski MA
J Thorac Oncol; 2007 Sep; 2(9):845-53. PubMed ID: 17805063
[TBL] [Abstract][Full Text] [Related]
17. [Lung cancer].
Furuse K
Gan To Kagaku Ryoho; 1997 Oct; 24(13):1917-24. PubMed ID: 9350236
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy in metastatic non-small-cell lung cancer.
Sandler A
Oncology (Williston Park); 2000 Jul; 14(7 Suppl 5):15-27. PubMed ID: 10981287
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Calvo AR; Belani CP
Cancer Treat Res; 2001; 105():189-227. PubMed ID: 11224988
[No Abstract] [Full Text] [Related]
20. Chemoradiation in locally advanced non-small cell lung cancer.
Bonomi P; Shirazi W
Cancer Treat Res; 2001; 105():171-88. PubMed ID: 11224987
[No Abstract] [Full Text] [Related]
[Next] [New Search]
